$141.37
-1.07-0.75%
Last update: Oct 12, 1:06 PM
Neurocrine Biosciences Inc
NBIXNASDAQ
Neurocrine Biosciences (NBIX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $2.10 | $1.61 | $2.09 | $1.87 |
| Actual | $2.85 | $1.94 | $1.88 | $2.17 |
| Surprise | +35.7% | +20.5% | -10.1% | +16.0% |
| Revenue | ||||
| Estimate | $876.6M | $763.1M | $786.7M | $745.8M |
| Actual | $959.0M | $814.5M | $805.5M | $794.9M |
| Surprise | +9.40% | +6.73% | +2.38% | +6.58% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $2.58 | $2.69 | $1.74 | $2.13 |
| Revenue | ||||
| Consensus | $1.04B | $1.08B | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $2.85 | $2.10 | 35.7 % |
| Q1 | May 5, 2026 | $1.94 | $1.61 | 20.5 % |
| Q4 | Feb 11, 2026 | $1.88 | $2.09 | -10.1 % |
| Q3 | Oct 28, 2025 | $2.17 | $1.87 | 16.0 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $959.00M | $876.59M | 9.40 % |
| Q1 | May 5, 2026 | $814.50M | $763.11M | 6.73 % |
| Q4 | Feb 11, 2026 | $805.50M | $786.75M | 2.38 % |
| Q3 | Oct 28, 2025 | $794.90M | $745.80M | 6.58 % |
